Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV
infection. However, PBL can also be seen in patients with other immunodeficiencies as well …

MYC is a potent oncogene initially identified as the target of the t (8; 14)(q24; q32)
chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified …

Epstein–Barr virus (EBV) is aetiologically linked to a wide range of human tumours. Some
arise as accidents of the virus' lifestyle in its natural niche, the B lymphoid system; these …

Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large
neoplastic cells, most of them resembling plasmablasts that have a CD20-negative …

Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma
frequently associated with immunosuppression, particularly human immunodeficiency virus …

Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype
frequently associated with immunosuppression. Clinically, patients with PBL are …

Background Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of
HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse …

Despite the introduction of highly active antiretroviral therapy or combination antiretroviral
therapy (HAART and cART, respectively) patients infected with HIV might develop certain …

Patients infected with human immunodeficiency virus (HIV) are at increased risk for
developing both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Even if this …

Background Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid
and plasmacytic differentiation that is commonly associated with immunodeficiency and an …